Philadelphia, May 15, 2018 In a study investigating the use of transcranial magnetic stimulation (TMS) for drug addiction, researchers at Medical University of South Carolina are the first to demonstrate that the noninvasive brain stimulation technique can dampen brain activity in response to drug cues in chronic alcohol users and chronic cocaine users. The findings are published in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging.
Although the last 50 years of clinical and preclinical research have demonstrated that addiction is a brain disease, there are still no neural circuit-based treatments for substance dependence or the brain functions involved in the disorder. "Here, for the first time, we demonstrate that a new non-invasive brain stimulation technique may be the first tool available to fill this critical void in addiction treatment development," said senior author Colleen Hanlon, PhD.
Elevated brain activity in response to drug cues--referred to as cue reactivity--occurs with many types of drugs, including nicotine, alcohol, marijuana, and cocaine. Cue reactivity also predicts relapse in addiction, so treatment approaches targeting the neural circuitry related to cue reactivity may directly impact cue-induced relapse in patients.
"Therefore, these results have a tremendous potential to impact both basic discovery neuroscience as well as targeted clinical treatment development for substance dependence," said Dr. Hanlon.
First author of the paper Tonisha Kearney-Ramos, PhD, and colleagues performed two independent studies at the same time, one involving 25 people with cocaine use disorder and the other involving 24 people with alcohol use disorder. The participants received one session of TMS, which targeted magnetic stimulation to circuitry critical for drug-taking behaviors--the ventromedial prefrontal cortex. The real stimulation session was compared against a sham session that mimicked the experience of receiving TMS without actual brain stimulation.
Brain imaging before and after TMS revealed that when alcohol users viewed images of alcohol-related cues, such as a liquor bottle, the single TMS session significantly reduced their drug cue reactivity. The same was true for cocaine users when viewing images of cocaine-related cues.
"Since cue reactivity has previously been associated with abstinence, these studies suggest a common mechanism for treatment effects across disorders, with fMRI serving as a promising neural readout of treatment effects," said Cameron Carter, MD, Editor of Biological Psychiatry: Cognitive Neuroscience and Neuroimaging.
However, it is still unclear if the changes in brain activity observed in the study will translate to reduced drug or alcohol use. The participants did not report any changes in their drug or alcohol craving after TMS. The authors think that repeated sessions of the targeted stimulation may be needed to see changes in self-reported craving. The researchers hope to answer this question in an ongoing clinical trial involving multiple TMS sessions in cocaine users.
In addition to substance abuse, elevated cue-reactivity is a core symptom of many diseases, such as post-traumatic stress disorder, generalized anxiety disorder, traumatic brain injury, smoking, and obesity, said Dr. Hanlon. "Therefore, the treatment described in this manuscript may have implications far beyond the substance abuse field."
Notes for editors
The article is "Transdiagnostic Effects of Ventromedial Prefrontal Cortex Transcranial Magnetic Stimulation on Cue Reactivity," by Tonisha E Kearney-Ramos, Logan T Dowdle, Daniel H Lench, Oliver L Mithoefer, William Devrie, Mark S George, Raymond F Anton, and Colleen A Hanlon. (https:/
Copies of this paper are available to credentialed journalists upon request; please contact Rhiannon Bugno at BPCNNI@UTSouthwestern.edu or +1 214 648 0880. Journalists wishing to interview the authors may contact Colleen Hanlon at firstname.lastname@example.org">email@example.com.
The authors' affiliations and disclosures of financial and conflicts of interests are available in the article.
Cameron S. Carter, MD, is Professor of Psychiatry and Psychology and Director of the Center for Neuroscience at the University of California, Davis. His disclosures of financial and conflicts of interests are available here.
About Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging is an official journal of the Society of Biological Psychiatry, whose purpose is to promote excellence in scientific research and education in fields that investigate the nature, causes, mechanisms and treatments of disorders of thought, emotion, or behavior. In accord with this mission, this peer-reviewed, rapid-publication, international journal focuses on studies using the tools and constructs of cognitive neuroscience, including the full range of non-invasive neuroimaging and human extra- and intracranial physiological recording methodologies. It publishes both basic and clinical studies, including those that incorporate genetic data, pharmacological challenges, and computational modeling approaches.
Elsevier is a global information analytics business that helps institutions and professionals advance healthcare, open science and improve performance for the benefit of humanity. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support and professional education, including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, more than 38,000 e-book titles and many iconic reference works, including Gray's Anatomy. Elsevier is part of RELX Group, a global provider of information and analytics for professionals and business customers across industries. http://www.
Editorial Office, Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
+1 214 648 0880